PCB Bancorp Declares Quarterly Cash Dividend of $0.20 Per Common Share
About PCB Bancorp
PCB Bancorp is the bank holding company for PCB Bank, a California state chartered bank, offering a full suite of commercial banking services to small to medium-sized businesses, individuals and professionals, primarily in Southern California, and predominantly in Korean-American and other minority communities.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Viking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial
We recently compiled a list of Viking Therapeutics, Inc. stands third on our list. Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharma company developing treatments for metabolic and endocrine disorders, including obesity, NASH, and rare diseases like X-linked adrenoleukodystrophy (X-ALD). Its lead candidate, VK2735—a dual GLP-1/GIP receptor agonist- is now in Phase 3 VANQUISH trials for obesity and obesity with type 2 diabetes, following strong Phase 1 and 2 results demonstrating significant weight loss and safety, making it one of the best growth stocks in the biotech sector. Viking Therapeutics, Inc. (NASDAQ:VKTX) has also completed enrollment in a Phase 2 trial for an oral version of VK2735, with top-line results expected in the second half of 2025. If successful, the oral formulation could offer a more convenient alternative to injectable obesity drugs. The company is further expanding its pipeline with a novel amylin agonist program aimed at metabolic disorders, expecting to file an IND by Q4 2025. Additionally, VK2809, a thyroid hormone receptor beta agonist for NASH, has shown positive Phase 2b results. The business is also advancing VK0214 for X-ALD and other programs targeting lipid metabolism. A scientist in the lab, researching the development of biopharmaceutical monoclonal antibody drugs. With a robust pipeline and $808 million in cash (as of June 2025), Viking Therapeutics, Inc. (NASDAQ:VKTX) is well-positioned to fund upcoming milestones. The Phase 3 VK2735 trials and pending oral trial results are key near-term catalysts. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
6 minutes ago
- Yahoo
AM Best Affirms Credit Ratings of The Hanover Insurance Group, Inc. and Its Subsidiaries
OLDWICK, N.J., July 31, 2025--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of "a+" (Excellent) of the property/casualty subsidiaries of The Hanover Insurance Group, Inc. [NYSE: THG], which are collectively referred to as The Hanover. Additionally, AM Best has affirmed the Long-Term ICR of "bbb+" (Good) and all Long-Term Issue Credit Ratings (Long-Term IR) of The Hanover Insurance Group, Inc., which is the parent holding company. The outlook of these Credit Ratings (ratings) is stable. All companies are headquartered in Worcester, MA. (See below for a detailed listing of the companies and ratings.) The ratings reflect The Hanover's balance sheet strength, which AM Best assesses at the strongest level, as well as its adequate operating performance, favorable business profile and appropriate enterprise risk management (ERM). The Hanover's balance sheet strength assessment is supported by its risk-adjusted capitalization, which is at the strongest level, as measured by Best's Capital Adequacy Ratio (BCAR). The overall balance sheet strength assessment also considers the solid organic surplus growth over the recent five-year period despite ongoing stockholder dividends, as well as the group's stable loss reserve position and favorable development patterns. Balance sheet strength also reflects the comprehensive reinsurance program and the benefits derived from the additional financial flexibility available through the parent company, The Hanover Insurance Group, Inc. These positive factors are offset somewhat by higher premium and underwriting leverage measures, as well as the group's regional exposure to natural catastrophe and terror events. The Hanover's financial leverage remains within acceptable levels relative to the group's current ratings with improved interest coverage. The Hanover's ratings reflect its adequate operating performance. While pre-tax operating earnings have trailed the commercial casualty composite over the long term, improved operating performance in 2024 reflects ongoing initiatives to enhance results inclusive of additional rate, combined with a reduction in reported catastrophe losses relative to 2023. Rate and exposure increases drove strong top-line growth in commercial lines in 2024 as results benefited from lower catastrophe losses combined with favorable reserve development on prior-year losses. The decline in catastrophe losses in 2024 led to improvement in personal lines results, which benefit from ongoing exposure management initiatives, combined with the benefit of earned premium reflective of ongoing rate improvement. Recent 2024 initiatives, which are showing demonstrated earnings improvement include ongoing rate actions, in combination with higher insurance-to-value ratios, increases in deductibles for roofs and all perils, as well as selective non renewals where appropriate. The ratings also consider the group's favorable business profile and diversified product offerings, especially within its commercial and specialty lines of business. The Hanover's business profile assessment reflects its strong market position, reflective of its leading position in many of its targeted niche segments, as well as an experienced management team. The group's product range includes personal lines, core commercial offerings and specialty coverages, with business expansion supported by strong relationships with its independent agency partners. The Hanover has implemented an appropriately designed and embedded ERM program to address the organization's risks. The group's ERM program is appropriate for the scale, scope, and complexity of the organization and the ability to monitor key risks and tolerances is well-established. The FSR of A (Excellent) and the Long-Term ICRs of "a+" (Excellent) have been affirmed with stable outlooks for the following subsidiaries of The Hanover Insurance Group, Inc.: AIX Specialty Insurance Company Allmerica Financial Alliance Insurance Company Allmerica Financial Benefit Insurance Company Campmed Casualty & Indemnity Company, Inc. Citizens Insurance Company of America Citizens Insurance Company of Ohio Citizens Insurance Company of the Midwest Citizens Insurance Company of Illinois The Hanover American Insurance Company The Hanover Atlantic Insurance Company Ltd. The Hanover Insurance Company The Hanover Casualty Company (formerly known as Hanover Lloyd's Insurance Company) Massachusetts Bay Insurance Company NOVA Casualty Company Verlan Fire Insurance Company The following Long-Term IRs have been affirmed with a stable outlook: The Hanover Insurance Group, Inc.— -- "bbb+" (Good) on $199.5 million 7.625% senior unsecured debentures, due 2025 (of which $61.8 million remains outstanding)-- "bbb+" (Good) on $375.0 million 4.5% senior unsecured fixed rate notes, due 2026-- "bbb-" (Good) on $165.7 million 8.207% subordinated deferrable debentures, due 2027 (of which $50.1 million remains outstanding)-- "bbb+" (Good) on $300 million 2.5% senior unsecured notes, due 2030 The following indicative Long-Term IRs under the shelf registration have been affirmed with a stable outlook: The Hanover Insurance Group, Inc.— -- "bbb+" (Good) on senior unsecured debt-- "bbb-" (Good) on subordinated debt-- "bbb-" (Good) on preferred stock This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments. AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit Copyright © 2025 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED. View source version on Contacts Gordon McLean Senior Financial Analyst +1 908 882 2109 Rosemarie Mirabella Director +1 908 882 2125 Christopher Sharkey Associate Director, Public Relations +1 908 882 2310 Al Slavin Senior Public Relations Specialist +1 908 882 2318 Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
6 minutes ago
- Yahoo
Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug
We recently compiled a list of Apogee Therapeutics, Inc. stands fourth on our list. Apogee Therapeutics, Inc. (NASDAQ:APGE) is a clinical-stage biotech company developing novel antibody-based therapies for inflammatory and immunology (I&I) conditions, including atopic dermatitis (AD), asthma, eosinophilic esophagitis, and COPD. Using advanced antibody engineering, the company aims to improve efficacy and extend dosing intervals, addressing major unmet needs in these large markets. In July 2025, Apogee Therapeutics, Inc. (NASDAQ:APGE) reported positive 16-week results from its Phase 2 APEX trial of APG777, an anti-IL-13 antibody for moderate-to-severe AD. The data demonstrated strong efficacy and safety, positioning APG777 as a potential best-in-class therapy with differentiated dosing advantages. The company held a webcast on July 7 to discuss these promising results, which support advancing the candidate to later-stage trials. A biotechnologist in a lab coat discussing a therapeutic antibody with a colleague. The business's pipeline also includes APG990, which showed favorable pharmacokinetics in Phase 1 trials, suggesting it could be administered as infrequently as every three to six months. The combination of APG777 and APG990 reflects Apogee Therapeutics, Inc. (NASDAQ:APGE)'s strategy to deliver long-acting, highly effective treatments for chronic inflammatory diseases. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
